NO20032531D0 - Tetralon-derivater som antitumormidler - Google Patents

Tetralon-derivater som antitumormidler

Info

Publication number
NO20032531D0
NO20032531D0 NO20032531A NO20032531A NO20032531D0 NO 20032531 D0 NO20032531 D0 NO 20032531D0 NO 20032531 A NO20032531 A NO 20032531A NO 20032531 A NO20032531 A NO 20032531A NO 20032531 D0 NO20032531 D0 NO 20032531D0
Authority
NO
Norway
Prior art keywords
antitumor agents
tetralone derivatives
tetralone
derivatives
antitumor
Prior art date
Application number
NO20032531A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032531L (no
Inventor
Guy Georges
Adelbert Grossmann
Tim Sattelkau
Wolfgang Schaefer
Ulrich Tibes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20032531L publication Critical patent/NO20032531L/no
Publication of NO20032531D0 publication Critical patent/NO20032531D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20032531A 2000-12-07 2003-06-04 Tetralon-derivater som antitumormidler NO20032531D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en) 2000-12-07 2001-12-06 Tetralone derivatives as antitumor agents

Publications (2)

Publication Number Publication Date
NO20032531L NO20032531L (no) 2003-06-04
NO20032531D0 true NO20032531D0 (no) 2003-06-04

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032531A NO20032531D0 (no) 2000-12-07 2003-06-04 Tetralon-derivater som antitumormidler

Country Status (25)

Country Link
US (1) US6531472B2 (cs)
EP (1) EP1349830A1 (cs)
JP (1) JP4091431B2 (cs)
KR (1) KR20030077551A (cs)
CN (1) CN100340545C (cs)
AR (1) AR035659A1 (cs)
AU (2) AU2002216074C1 (cs)
BG (1) BG107889A (cs)
BR (1) BR0115988A (cs)
CA (1) CA2430355A1 (cs)
CZ (1) CZ20031833A3 (cs)
EC (1) ECSP034642A (cs)
HR (1) HRP20030451A2 (cs)
HU (1) HUP0400579A2 (cs)
IL (1) IL156133A0 (cs)
MA (1) MA26972A1 (cs)
MX (1) MXPA03004947A (cs)
NO (1) NO20032531D0 (cs)
NZ (1) NZ526051A (cs)
PL (1) PL365324A1 (cs)
RU (1) RU2288220C2 (cs)
SK (1) SK8512003A3 (cs)
WO (1) WO2002046144A1 (cs)
YU (1) YU45803A (cs)
ZA (1) ZA200304262B (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
RU2320331C2 (ru) 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
CA2481466A1 (en) * 2002-04-05 2003-10-16 Yoshinori Naoe Depsipeptide for therapy of kidney cancer
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2508052A1 (en) * 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ545935A (en) 2003-08-26 2009-02-28 Merck Hdac Res Llc Method of treating cancer with HDAC inhibitors
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
CA2561954A1 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3052662B1 (en) 2013-10-01 2019-05-15 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3062783B1 (en) * 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2020205455A1 (en) * 2019-03-29 2020-10-08 Taiwanj Pharmaceuticals, Co., Ltd. Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20250213523A1 (en) 2022-04-05 2025-07-03 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
HRP20030451A2 (en) 2005-04-30
SK8512003A3 (en) 2004-04-06
YU45803A (sh) 2006-05-25
KR20030077551A (ko) 2003-10-01
MXPA03004947A (es) 2003-09-10
AU1607402A (en) 2002-06-18
AU2002216074C1 (en) 2006-12-07
HK1060875A1 (en) 2004-08-27
AR035659A1 (es) 2004-06-23
HUP0400579A2 (hu) 2004-06-28
EP1349830A1 (en) 2003-10-08
ECSP034642A (es) 2003-07-25
AU2002216074B2 (en) 2006-01-05
NO20032531L (no) 2003-06-04
MA26972A1 (fr) 2004-12-20
US20020065282A1 (en) 2002-05-30
BG107889A (bg) 2004-06-30
WO2002046144A1 (en) 2002-06-13
CN100340545C (zh) 2007-10-03
JP4091431B2 (ja) 2008-05-28
IL156133A0 (en) 2003-12-23
US6531472B2 (en) 2003-03-11
CN1478072A (zh) 2004-02-25
ZA200304262B (en) 2004-08-30
CA2430355A1 (en) 2002-06-13
BR0115988A (pt) 2004-01-13
JP2004515488A (ja) 2004-05-27
PL365324A1 (en) 2004-12-27
CZ20031833A3 (cs) 2004-02-18
NZ526051A (en) 2004-12-24
RU2288220C2 (ru) 2006-11-27

Similar Documents

Publication Publication Date Title
NO20032531D0 (no) Tetralon-derivater som antitumormidler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DK1326858T3 (da) Piperidinforbindelser som anti-allergiske midler
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1322654T3 (da) Platinkomplekser som antitumormidler
DE50114491D1 (de) Substituierte C-Cyclohexylmethylamin-Derivative
NO20034647L (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1263734T3 (da) 3-thiomethylpyrazoler som pesticider
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
PT1351959E (pt) Novos derivados de pleuromutilina
NO20014753L (no) C(10)-karbonatsubstituerte taxaner som antitumormidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application